Assessment of intestinal inflammation via fecal calprotectin for early prediction of adverse outcomes in advanced chronic liver disease
United European Gastroenterology Journal · 2025
DOI: 10.1002/ueg2.12633 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Tomas Koller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Subdivision, Department of Internal Medicine 5, Comenius University Faculty of Medicine and University Hospital, Brat…. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Feces, Liver Diseases, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and aims Intestinal inflammation assessed by fecal calprotectin (F‐CAL) in advanced chronic liver disease (ACLD) may represent an early sign of intestinal barrier dysfunction. We aimed to explore the usefulness of F‐CAL testing in ACLD in the prediction of adverse outcomes (AO, death, or LT) and refinement of prognostic stratification. Patients and methods We explored the RH7 cirrhosis registry comprising consecutive hospitalized patients and a control group with data on disease phenotype, demographics, anthropometrics, prognostic indices, and medication. The F‐CAL was evaluated on admission and reported in multiples of the upper limit of normal or terciles. Predictive power was tested in the Cox model for AO over 180 days. Additional risk refinement by F‐CAL was tested for both groups.
Results
We enrolled 263 cases in the study group with a median age of 57.2 years, M/F ratio 167/96, with alcohol, metabolic dysfunction‐associated steatotic liver disease, MetALD, and viral etiologies in 72.2%, 9.1, 8.0, 3.4%. The median F‐CAL was 3.92 × ULN. The control group comprised 108 cases. The adjusted Cox model confirmed F‐CAL (hazard ratio [HR] = 1.05, p < 0.001) and F‐CAL terciles (HR = 1.413, p = 0.009) as independent predictors of AO. F‐CAL terciles had higher predictive accuracy in CLIF‐C‐AD11 × ULN) could identify patients having 2–3 times higher risk of AO. This approach has been validated in the control group.
Conclusion
Among hospitalized patients with ACLD, F‐CAL values were independently proportional to the risk of AO, particularly in early disease stages when high F‐CAL values could refine prognostic stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Hepatology Subdivision, Department of Internal Medicine 5, Comenius University Faculty of Medicine and University Hospital, Bratislava, Slovakia.
- Department of Hepatology, Gastroenterology and Transplantation (HEGITO), Department of Internal Medicine 2, Slovak Medical University and FD Roosevelt Hospital, Banska Bystrica, Slovakia.
ORCID-Profile: Tomas Koller, Petra Vrbova, Natalia Kubanek, Daniela Zilincanova, Svetlana Adamcova Selcanova, Daniel Jan Havaj, Lubomir Skladany
Zitieren
APA
Koller, T., Vrbova, P., Kubanek, N., Zilincanova, D., Selcanova, S. A., Havaj, D. J., & Skladany, L. (2025). Assessment of intestinal inflammation via fecal calprotectin for early prediction of adverse outcomes in advanced chronic liver disease. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12633
Vancouver
Koller T, Vrbova P, Kubanek N, Zilincanova D, Selcanova SA, Havaj DJ, et al. Assessment of intestinal inflammation via fecal calprotectin for early prediction of adverse outcomes in advanced chronic liver disease. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12633
BibTeX
@article{Koller2025,
author = {Koller, Tomas and Vrbova, Petra and Kubanek, Natalia and Zilincanova, Daniela and Selcanova, Svetlana Adamcova and Havaj, Daniel Jan and Skladany, Lubomir},
title = {Assessment of intestinal inflammation via fecal calprotectin for early prediction of adverse outcomes in advanced chronic liver disease},
journal = {United European Gastroenterology Journal},
year = {2025},
doi = {10.1002/ueg2.12633}
}
EUVIMED